MIND MEDICINE MINDMED INC (MNMD)
CA60255C8850 - Common Stock
MNMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While MNMD seems to be doing ok healthwise, there are quite some concerns on its profitability. MNMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year MNMD has reported negative net income.
In the past year MNMD has reported a negative cash flow from operations.
MNMD had negative earnings in each of the past 5 years.
MNMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MNMD has a Return On Assets (-30.59%) which is comparable to the rest of the industry.
MNMD has a Return On Equity of -37.30%. This is in the better half of the industry: MNMD outperforms 63.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.59% | ||
| ROE | -37.3% | ||
| ROIC | N/A |
ROA(3y)-55.67%
ROA(5y)-49.46%
ROE(3y)-73.83%
ROE(5y)-61.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, MNMD has more shares outstanding
Compared to 5 years ago, MNMD has more shares outstanding
Compared to 1 year ago, MNMD has a worse debt to assets ratio.
2.2 Solvency
MNMD has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
MNMD has a Debt to Equity ratio (0.09) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 9.00 indicates that MNMD has no problem at all paying its short term obligations.
MNMD has a better Current ratio (9.00) than 80.98% of its industry peers.
MNMD has a Quick Ratio of 9.00. This indicates that MNMD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MNMD (9.00) is better than 80.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9 | ||
| Quick Ratio | 9 |
3. Growth
3.1 Past
The earnings per share for MNMD have decreased strongly by -19.58% in the last year.
EPS 1Y (TTM)-19.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MNMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.56%
EPS Next 2Y17.02%
EPS Next 3Y9.26%
EPS Next 5Y18.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
No dividends for MNMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIND MEDICINE MINDMED INC
NASDAQ:MNMD (1/3/2025, 8:00:01 PM)
After market: 7.2196 +0.04 (+0.55%)7.18
-0.36 (-4.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners52.2%
Inst Owner Change17.05%
Ins Owners1.02%
Ins Owner Change-1.39%
Market Cap526.51M
Analysts85
Price Target27.16 (278.27%)
Short Float %13.03%
Short Ratio6.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.98%
Min EPS beat(2)5.46%
Max EPS beat(2)22.5%
EPS beat(4)2
Avg EPS beat(4)-27.11%
Min EPS beat(4)-111.45%
Max EPS beat(4)22.5%
EPS beat(8)4
Avg EPS beat(8)-8.01%
EPS beat(12)8
Avg EPS beat(12)6.82%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.15%
EPS NY rev (1m)2.93%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.01 | ||
| P/tB | 2.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.26
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpSN/A
BVpS3.58
TBVpS3.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.59% | ||
| ROE | -37.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-55.67%
ROA(5y)-49.46%
ROE(3y)-73.83%
ROE(5y)-61.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9 | ||
| Quick Ratio | 9 | ||
| Altman-Z | N/A |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y34.56%
EPS Next 2Y17.02%
EPS Next 3Y9.26%
EPS Next 5Y18.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.33%
EBIT Next 3Y-7.98%
EBIT Next 5Y14.14%
FCF growth 1Y-64.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.77%
OCF growth 3YN/A
OCF growth 5YN/A